Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: 5,17,37,5,101,... who wrote (192)	1/10/1999 6:01:00 PM
From: CPAMarty	Respond to of 2515

looks like institutions own 32.66% of the stock 411stocks.com

To: 5,17,37,5,101,... who wrote (192)	1/10/1999 7:16:00 PM
From: JEB	Read Replies (2) \| Respond to of 2515

Jackson, After reviewing the C225 drug, I have come to the conclusion that this company's product is superior to other cancer drugs coming to market. Let me explain, The C225 is used in conjunction with chemotherapy and radiation therapy. It kills the blood flow to the mass tumor while radiation or chemo destroys the cancerous tissue. Other drugs just coming out are not (IMO) a combined attack approach. This drug should be prescribed more than the others on the basis that an awful lot of physicians, nurses, and technicians have specialized in radiation and chemotherapy Oncology. They will need to transition to any new therapy's which do not use chemotherapy or radiation therapy. It will take time. Also, MRK seems to agree and offered a sweetheart deal. Thanks, JEB